Net profit rose 21% to €111.1M on revenue of €493.6M, driven by strong pharma and international sales. Dividend payout increased to €0.16 per share. See full details in the 2024 CNMV filing.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.